http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009198120-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bd72b79aaad47b42012258b186370ba3 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-4905 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-323 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-026 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-06 |
| filingDate | 2006-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_236808675c90f227b64f6c40491d1bab |
| publicationDate | 2009-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2009198120-A1 |
| titleOfInvention | Detection of restenosis risk in patients receiving a stent by measuring the characteristics of blood clotting including the measurement of maximum thrombin-induced clot strength |
| abstract | A method of selecting a stent for implantation in the circulatory system of a human being includes the steps of determining a threshold level of platelet hyper-coaguability (PHC). One marker of PHC is platelet-fibrin mediated clot strength (MA) of blood. MA above a threshold demonstrates a risk of restenosis that is relatively high. In practicing the method, a sample of blood is obtained from a patient who requires implantation of a stent, the blood sample is tested for its platelet-fibrin mediated clot strength, the clot strength of the blood sample is compared with the threshold level; if the blood sample has a clot strength below the threshold level, selecting a bare metal stent, and if the blood sample has a clot strength at or above the threshold level, selecting a drug-eluting stent. The method includes, in a preferred embodiment, use of a viscoelastic monitor to perform the testing step. Other markers of PHC may also be employed such as measurement of thrombin generation and/or platelet reactivity. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11598707-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11788941-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10823743-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10739239-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111579398-A |
| priorityDate | 2005-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 94.